Interaction between lung cancer cells and astrocytes via specific inflammatory cytokines in the microenvironment of brain metastasis by Seike, Toshihiro et al.
RESEARCH PAPER
Interaction between lung cancer cells and astrocytes via speciﬁc
inﬂammatory cytokines in the microenvironment of brain
metastasis
Toshihiro Seike • Kyota Fujita • Yukiko Yamakawa •
Mizuho A. Kido • Soichi Takiguchi • Norihiro Teramoto •
Haruo Iguchi • Mami Noda
Received: 13 July 2009/Accepted: 25 September 2010/Published online: 17 October 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract The incidence of brain metastasis is increasing,
however, little is known about molecular mechanism
responsible for lung cancer-derived brain metastasis and
their development in the brain. In the present study, brain
pathology was examined in an experimental model system
of brain metastasis as well as in human brain with lung
cancer metastasis. In an experimental model, after
3–6 weeks of intracardiac inoculation of human lung
cancer-derived (HARA-B) cells in nude mice, wide range
of brain metastases were observed. The brain sections
showed signiﬁcant increase in glial ﬁbrillary acidic protein
(GFAP)-positive astrocytes around metastatic lesions. To
elucidate the role of astrocytes in lung cancer proliferation,
the interaction between primary cultured mouse astrocytes
and HARA-B cells was analyzed in vitro. Co-cultures and
insert-cultures demonstrated that astrocytes were activated
by tumor cell-oriented factors; macrophage migration
inhibitory factor (MIF), interleukin-8 (IL-8) and plasmin-
ogen activator inhibitor-1 (PAI-1). Activated astrocytes
produced interleukin-6 (IL-6), tumor necrosis factor-a
(TNF-a) and interleukin-1 b (IL-1b), which in turn pro-
moted tumor cell proliferation. Semi-quantitative immu-
nocytochemistry showed that increased expression of
receptors for IL-6 and its subunits gp130 on HARA-B
cells. Receptors for TNF-a and IL-1b were also detected on
HARA-B cells but down-regulated after co-culture with
astrocytes. Insert-culture with astrocytes also stimulated
the proliferation of other lung cancer-derived cell lines
(PC-9, QG56, and EBC-1). These results suggest that
tumor cells and astrocytes stimulate each other and these
mutual relationships may be important to understand how
lung cancer cells metastasize and develop in the brain.
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Introduction
Metastasis is the principal cause of the morbidity and death
of cancer patients. The incidence of brain metastasis has
been increasing in recent years, especially in breast cancer
and lung cancer [1]. In the process of metastasis formation,
the interaction between the metastatic tumor cells and host
cells plays an important role in the microenvironment of
the metastatic sites [2]. However, a molecular mechanism
for brain metastasis is poorly understood to date. In the
central nervous system, activated glial cells contribute to
the innate immune response and produce a large variety of
different inﬂammatory mediators as a chronic inﬂamma-
tory reaction [3]. A similar mechanism could function in
cell survival, growth, proliferation and colonization, inva-
sion and motility of metastatic tumor cells in the micro-
environment of brain metastases [4, 5]. Among the glial
cells, astrocytes are the most abundant cell population and
play an important role in maintaining homeostasis of the
brain [6]. Astrocytes have been shown to produce a
wide variety of cytokines including interleukin-1 (IL-1),
interleukin-3 (IL-3), interleukin-6 (IL-6), tumor necrosis
factor-a (TNF-a), transforming growth factor-b (TGF-b),
insulin-like growth factor-1 (IGF-1) and platelet-derived
growth factor (PDGF) [7–10]. Among them, it was sug-
gested that IL-6, TGF-b and IGF-1 may contribute to the
development of brain metastasis by breast cancer cells [11].
As for brain metastasis by lung cancer cells, it is not known
whether or not the same cytokines are involved and what
the difference between brain metastases derived by breast
cancer cells and lung cancer cells.
Therefore, in the present study, we examined brain
pathology in an experimental model system of brain
metastasis, using HARA-B cells derived from human lung
cancer cells, and assessed the effects of astrocytes on the
growth of HARA-B cells as well as three other non-small
cell lung cancer cell lines (PC-9, QG56, and EBC-1) in
vitro. Furthermore, astrocytes-derived factors conducive to
tumor cell growth and their receptor expression on tumor
cells were investigated.
Materials and methods
Experimental model for brain metastasis
The study was approved by the Animal Care and Use
Committee at Kyushu University and carried out in
accordance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. Male 5-week-old
nude mice (BALB/c nu/nu) (Kyudo, Kumamoto, Japan),
kept in a speciﬁc pathogen-free environment, were used. A
single suspension of human lung squamous cell carcinoma-
derived cells (HARA-B) (2 9 10
5 cells/0.2 ml PBS) was
inoculated into the left ventricle of the heart in nude mice
according to the method described previously [12]. After
4–6 weeks, brains were subjected for immunohistochemi-
cal staining.
Human tissue samples
A total of 6 parafﬁn-embedded samples from patients with
lung tumor brain metastasis were used. All sections were
obtained from the National Hospital Organization Shikoku
Cancer Center. Use of the human specimens was in accor-
dance with the University Ethics Commission. The forma-
lin-ﬁxed, parafﬁn-embedded archival tissue blocks were
retrieved, and matching hematoxylin and eosin (H & E)-
stained slides were reviewed and screened for representa-
tive tumor regions by a neuropathologist.
Immunohistochemistry
Nude mice were perfused transcardially with 50 ml of 10
U/ml heparin and 0.5% procaine in PBS and 4% parafor-
maldehyde (PFA) in PBS prior to excision of the brain.
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protected for 24 h in PBS containing 20% sucrose. The
brain was cut into slices (30 lm thick) using a cryostat and
the sections were placed on glass slides. In order to acquire
the better immunoreactive images, sections were auto-
claved with 0.01 M citrate buffer solution (pH 6.0), per-
meabilized with 0.3% TritonX-100 in PBS for 15 min, and
then blocked in BlockAce (Dainippon Pharmaceutical,
Japan) for1 hat room temperature. Sections were incubated
with mouse anti-human cytokeratin monoclonal antibody
(AE1/AE3 pool of cytokeratin) (Dako, Glostrup, Denmark,
1:100) at 4C overnight. Biotinylated anti-mouse IgG
(Jackson, 1:200) were incubated for 2 h at room tempera-
ture, followed by the incubation with streptavidin Alexa488
(Molecular Probes, 1:500) for 2 h at room temperature. For
double-staining of cytokeratin and GFAP, sections were
incubated with Cy3-conjugated anti-GFAP antibody
(Sigma, USA) (1:1000) at 4C overnight after staining of
cytokeratin. Every treatment was followed by washing three
times with PBS containing 0.3% TritonX-100 for 5 min.
The sections were mounted in the Perma Fluor Aqueous
Mounting Medium (Thermo Shandon, Pittsburgh, PA,
USA) and analyzed with a confocal microscope (LSM510
META, Carl Zeiss, Co. Ltd. Germany). Z-stack images
were obtained from each section by LSM 510 META and
total intensity were calculated by LSM image browser.
As for human tissue samples, after removal of parafﬁn
in xylene and rehydration in a graded of alcohols (100%,
90%, 80%, 70%, 60%), sections were incubated for 30 min
in 0.05 M phosphate buffer pH 7.6 containing tripsin and
KCl for antigen retrieval. Then, the sections were incu-
bated for 1 h in 0.3% H2O2, and blocked in PBS containing
1% BSA and 5% normal donkey serum (Jackson Immuno
Research Laboratories Inc., West Grove, PA, USA) for 1 h
at room temperature. Then, the sections were incubated
with anti-GFAP antibody (ImmunoStar) (1:15) at 4C
overnight, goat anti-rabbit IgG Alexa 568 (Molecular
Probes) (1:500) for 3 h at room temperature and FITC-
conjugated anti-human cytokeratin antibody (CAM5.2)
(Becton–Dickinson Biosciences, New Jersey, USA)
(undiluted solution) for 1 h at room temperature. Every
treatment was followed by washing three times with PBS
containing 0.3% TritonX-100 for 5 min. The sections were
mounted in the Perma Fluor Aqueous Mounting Medium
(Thermo Shandon, Pittsburgh, PA, USA) and analyzed
with a confocal microscope (LSM510 META, Carl Zeiss,
Co. Ltd. Germany).
Cell culture
Primary glial cell cultures were performed according to the
method described previously [13]. Brieﬂy, the cerebral
cortex obtained from 1-day-old C57BL/6 mice (Kyudo,
Kumamoto, Japan) were isolated under a dissecting
microscope and carefully separated from the choroid plexus
and meninges. The isolated cerebral cortex were minced
and treated with trypsin–EDTA solution (0.25% trypsin,
1 mM EDTA) and 1500 U DNase in Dulbecco’s modiﬁed
Egle medium (DMEM; Nissui, Tokyo, Japan) at 37C for
10 min. Cell suspensions were ﬁltered through 70 lm pore
size mesh (BD Falcon, Bedford, MA, USA) into DMEM
containing 10% fetal calf serum (FCS; Hyclone, UT, USA),
2 mM L-glutamine, 100 U/ml penicillin, 100 lg/ml strep-
tomycin, 0.37% NaHCO3, and 110 lg/ml pyruvic acid.
After centrifugation, cells were ﬁltered through 40 lm pore
size-mesh (BD Falcon), plated into poly-L-lysine coated
75 cm
2 cell culture ﬂask at the density of two brains per
ﬂask in 10 ml of DMEM, and maintained at 37C in 10%
CO2–90% air with a change of the medium twice per week.
Astrocytes were obtained after 28 days of mixed glial cell
cultures as follows. After removing other glial cells by
shaking the ﬂasks, the astroglial layer was removed from
the ﬂasks by the treatment with trypsin–EDTA solution
(0.06% trypsin, 0.25 mM EDTA in serum free DMEM) at
37C for 45 min. Suspended astrocytes were ﬁltered
through 40 lm pore size-mesh and seeded. Astrocyte purity
ranged from 90 to 95% as determined by immunostaining
with anti-GFAP antibody (Sigma, St. Louis, MO, USA)
(data not shown). Astrocytes were maintained in the same
medium used for cell suspension from cerebral cortex at
37C in 10% CO2–90% air. HARA-B cells and other lung
cancer cell lines (QG56, EBC-1; squamous cell carcinoma)
and PC-9 (non-small cell lung cancer cell) were maintained
under the same condition. Cells were grown in 25 cm
2 cell
culture ﬂask (Nalge Nunc International), and single-cell
suspension of cells were obtained by trypsin treatment.
Cell proliferation assay
In the co-culture experiment, HARA-B cells (0.5 9 10
3
cells/well) and astrocytes (2.5 9 10
3 or 5 9 10
3 cells/well)
were seeded into 8-well cell culture slide (BD Falcon) in
DMEM for 24 h. Then, cells were rinsed twice with PBS
and incubated in serum free DMEM. After 72 h of
co-culture, cells were ﬁxed with 4% PFA for 30 min at
room temperature and permeabilized with 0.3% TritonX-
100 in PBS for 15 min, followed with blocking solution
containing 1% BSA and 5% normal donkey serum (Jack-
son) in PBS for 1 h at room temperature. Then cells were
incubated with mouse anti-human cytokeratin monoclonal
antibody (AE1/AE3 pool of cytokeratin) (Dako, Glostrup,
Denmark) (1:100) at 4C overnight, followed by the
incubation with the secondary antibody (FITC-conjugated
anti-mouse IgG; Sigma, 1:500) for 5 h at room tempera-
ture, and then, incubated with 300 nM 40,60-diamidino-
2-phenylindole hydrochloride (DAPI, Sigma) for 30 min at
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123room temperature. The number of HARA-B cells in each
well, which were positively stained with an anti-human
cytokeratin antibody, was counted using a digital camera
system (Axio Cam, Carl Zeiss) mounted on a light and
ﬂuorescent microscope (Axopscope2 plus, Carl Zeiss). The
results were expressed as the percentage of control (single
cell culture of HARA-B cells).
Insert culture-medium was obtained as follows. Astro-
cytes (5 9 10
4 cells/well) were plated in 6-well cell culture
plates (Falcon). Tumor cells derived from each lung tumor
(EBC-1, PC9, QG56 and HARA-B cells) (5 9 10
3 cells/
insert) were plated in cell culture-inserts (membrane pore
size 0.4 lm; Becton–Dickinson), and then, placed in the
well of astrocyte cultures. After 24 h of the insert-culture,
cells were rinsed twice with PBS, incubated in serum-free
DMEM for further 48 h. Then, the medium was collected.
Each conditioned medium was centrifuged to remove
debris (1500 rpm for 10 min at 4C) before use. Tumor
cells derived from each lung tumor (0.5 9 10
3 cells/well)
were seeded into 8-well cell culture slide (BD Falcon) in
DMEM for 24 h. Then, cells were rinsed twice with PBS
and incubated in each Insert culture-medium. After 72 h,
cells were ﬁxed with 4% PFA for 30 min at room tem-
perature and incubated with 300 nM DAPI for 10 min at
room temperature. The number of tumor cells in each well,
which were positively stained with DAPI, was counted as
mentioned above. The results were expressed as the per-
centage of control (each tumor cells cultured in serum-free
DMEM for 72 h).
The astrocyte-conditioned medium (ACM) was obtained
from the primary culture of astrocytes at a density of 10
4
cells/well in serum free DMEM after 72 h-incubation. This
ACM was centrifuged (1500 rpm for 10 min at 4C), and
then, added to HARA-B cells cultured for 1 day at a vol-
ume of 25% or 50%. The number of HARA-B cells were
counted after the 72 h-incubation in the presence of ACM
as described above.
HARA-B-stimulated astrocyte-conditioned medium
(H-ACM) was obtained as follows. Culture medium of
HARA-B cells (5 9 10
3 cells/well) were added to astro-
cytes cultures (5 9 10
4 cells/well) and incubated for 24 h.
Then the medium was collected and centrifuged to remove
debris (1500 rpm for 10 min at 4C) before use.
In the proliferation assay using recombinant mouse
cytokines, HARA-B cells 24 h after plating were rinsed
twice with PBS and incubated in serum free DMEM with
each cytokine (mIL-1b, 1 to 10 pg/ml; mTNF-a,1 0t o
500 pg/ml; mIL-6, 10 to 500 pg/ml, Peprotech, Rocky Hill,
NJ, USA). After 72 h, HARA-B cells were immunostained
and counted as mentioned above.
In the experiments using neutralizing antibodies, cells
were plated, rinsed twice with PBS after 24 h, and incu-
bated in serum free DMEM with each speciﬁc neutralizing
antibodies; mIL-1b antibody (ab), 0.2 to 2.0 lg/ml (R&D
systems, Minneapolis, MN USA), mTNF-a ab, 0.2 to
2.0 lg/ml (R&D systems), mIL-6 ab, 2.0 to 20 ng/ml
(Peprotech) for 48 h. As controls, rat IgG (Sigma) and
rabbit IgG (R&D systems) were used. HARA-B cells were
immunostained and counted as mentioned above.
SYBR green-based real-time quantitative RT–PCR
HARA-B cells (1 9 10
5 cells/insert) and astrocytes
(1 9 10
6 cells/well) were cultured in cell culture-insert
systems as mentioned above. Cells were collected by
treatment with trypsin after 24, 48 and 72 h of insert-cul-
ture. As controls, single cell culture of HARA-B cells or
astrocytes was used. Total RNA was isolated from each
cell type by an extraction procedure using the RNA blood
mini kit (QIAGEN in Japan). Contaminating DNA was
removed by RNase-free DNase (QIAGEN). Single-strand
cDNA was synthesized from cellular mRNA by using
random 9 mer and RNA PCR kit (AMV) (Takara Bio Inc.,
Ootsu, Japan). PCR ampliﬁcation was undertaken for plain
SYBR Green I detection in using Light Cycler system
(Roche Diagnostics GmbH, Mannheim, Germany). Each
reaction was carried out in a total volume of 20 ll in glass
capillary, containing 1 ll of cDNA, 2, 3 or 4 mM MgCl2,
10% LightCycler-DNA Master SYBR Green I buffer (Taq
DNA polymerase, reaction buffer, deoxynucleotide tri-
phosphate mix, 10 mM MgCl2 and SYBR Green I dye) and
0.5 lM of each primer (Table 1). After the PCR reaction,
we conﬁrmed that there was no primer dimer and non
speciﬁc product in each PCR product by agarose gel
electrophoresis and staining with ethidium bromide. The
expression of all target genes was normalized to b-actin.
Analysis was carried out with Light Cycler 3.5 software
(Roche) and Microsoft Excel.
To see the reconstituted effects of HARA-B-derived
substances on astrocytic expression of TNF-a, IL-1b and
IL-6, the mouse primary astrocyte cells were treated with
human IL-8 (R&D systems, Minneapolis, MN, U.S.A),
MIF (R&D systems), or PAI-1 (Peprotech, Rocky Hill,
U.S.A) for 72 h in serum-free medium. Total RNA was
extracted using an RNeasy Plus Mini kit (QIAGEN,
Hilden, Germany) and QIA shredder (QIAGEN). cDNA
was synthesized using a SuperScript VILO cDNA synthe-
sis kit (Invitrogen) SYBR-Green real-time PCR (Applied
Biosystems, Foster City, CA) was performed on cDNA
prepared from each sample using Platinum SYBR-Green
qPCR Super-Mix-UDG (Invitrogen) and 0.5 lM each pri-
mer (Table 1). Thermal cycling condition were 10 min at
95C, 45 cycles at 95C for 15 s, followed by 1 min at
60C. Data Analysis was completed using the ABI PRISM
7500HT Sequence detection software (Applied Biosys-
tems). b-actin was used for normalization.
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123Cytokine ELISA assay
Co-cultures of HARA-B cells (0.5 9 10
3 cells/well) and
astrocytes (5 9 10
3 cells/well) or astrocytes alone (5 9 10
3
cells/well) were seeded into 8-well cell culture slides in
DMEM with FCS for 24 h. Then, cells were rinsed twice
with PBS and incubated in serum free DMEM. After 48 or
72 h of culture, each conditioned medium was collected and
centrifuged to remove debris (1500 rpm for 10 min at 4C)
before use. The amount of mouse IL-1b, TNF-a and IL-6 in
each conditioned medium was measured with an ELISA kit
for mouse cytokines (Biosource International). The absor-
bency at 450 nm was measured by a Microplate Reader
(Immuno-Mini NJ-2300, Nalge Nunc International).
Cytokine proteome array
HARA-B cells (1 9 10
6 cells) were grown in 10 cm dish
(BD, Franklin Lake, NJ, U.S.A) for 24 h and culture
medium was collected. Protein array analysis was per-
formed according to the manufacture’s instruction. Positive
controls were located in the upper left-hand corner (two
spots), upper right-hand corner (two spots) and the lower
left-hand corner (two spots) of each array kit. Medium and
culture medium were measured using the human cytokine
array Panel A (Proteome Proﬁler) (R&D systems, Minne-
apolis, MN, U.S.A). Horseradish peroxidase substrate
(Thermo scientiﬁc, Rockford, IL, U.S.A) was used to
detect protein expression and captured by exposure to
X-ray Film (FUJIFILM, Tokyo, Japan).
Immunocytochemistry
HARA-B cells (0.5 9 10
3 cells/well) with or without
astrocytes (5 9 10
3 cells/well) were seeded into 8-well cell
culture slides in complete medium. Cells were ﬁxed with
4% PFA for 30 min at room temperature and permeabili-
zed with 0.3% TritonX-100 in PBS for 15 min and blocked
Table 1 Gene-speciﬁc primer
pairs for real-time RT–PCR
Primer sequence (50–30) Length (bp)
Mouse
b-actin Sense ACCAACTGGGACGACATGGAG 380
Antisense GTGGTG GTGAAG CTGTAGCC
IL-6 Sense ACAAGTCGGAGGCTTAATTACACAT 79
Antisense AATCAG AATTG CCATTGCACAA
IL-1b Sense CTCCATGAG CTTTGTACAAG G 240
Antisense TG CTG ATGTACCAGTTG GG G
TNF-a Sense ATGAGCACAGAAAGCATGATCCGC 692
Antisense CCAAAGTAGACCTG CCCG GACTC
TGF-b1 Sense GAG AG CCCTGG GATACCAACTACTG 173
Antisense GTGTGTCCAGG CTCCAAATGTAG
EGF Sense TTTTGCCTCAGAAG GAGTGG 150
Antisense GG CCACACTTG G CAGTATATC
IGF-I Sense GGACCAGAGACCCTTTGCGGGG 209
Antisense GG CTG CTTTTGTAGG CTTCAGTG G
PDGF-B Sense TGAAATGCTGAGCGACCAC 137
Antisense AGCTTTCCAACTCGACTCC
Human
b-actin Sense ATG GCCACG GCTGCTTCCAG C 237
Antisense CATGGTGGTGACAGACCG CCG
IL-6Ra Sense CATTGCCATTGTTCTGAGGTT 271
Antisense AGTAGTCTGTATTG CTGATGT
gpi30 Sense TGGAGTGAAGAAGCAAGTGG 303
Antisense AACAGCTGCATCTGATTTGC
TNFRI Sense TG CCTACCCCAGATTG AG AA 121
Antisense ATTTCCCACAAACAATGGAGTAG
IL-1 Rtl Sense AAG GTG GAG G ATTCAGG ACAT 284
Antisense AG CCTATCTTTGACTCCACTA
IL-1 ra Sense CAGAAGACCTCCTGTCCTATGAGG 424
Antisense GCTGTGCAGAGGAACCA
Clin Exp Metastasis (2011) 28:13–25 17
123in PBS containing 1% BSA and 5% normal donkey serum
(Jackson) for 1 h at room temperature. Cells were incu-
bated with primary antibodies, containing monoclonal
mouse anti-human cytokeratin antibody (AE1/AE3 pool of
cytokeratin) (Dako, 1:100), rabbit anti-human IL-6Ra
antibody (Santa Cruz, CA, USA) (1:200), rabbit anti-
human gp130 antibody (Santa Cruz, 1:500), rabbit anti-
human IL-1RtI antibody (Santa Cruz, 1:200), and goat
anti-human TNFRI (Santa Cruz, 1:100) overnight at 4C.
Control cells were incubated without primary antibody
(PBS containing 1% BSA) to test non-speciﬁc staining.
The cells were then incubated for 5 h at room temperature
with secondary antibody, containing FITC-conjugated anti-
mouse IgG (Sigma, 1:500), Cy3-conjugated anti-rabbit
IgG (Jackson, 1:500) and Cy3-conjugated anti-goat IgG
(Jackson, 1:500) and then for 30 min at room temperature
with 300 nM 40,60-diamidino-2-phenylindole hydrochloride
(DAPI, Sigma). Slides were mounted in the Perma Fluor
Aqueous Mounting Medium (Thermo) and were analyzed
with a Zeiss LSM510 META confocal microscope.
Statistical analysis
One-way analysis of variance (ANOVA) and post-hoc
Bonferroni/Dunn test were used to examine the statistical
differences. Differences were considered signiﬁcant at
P\0.05.
Results
Histological analyses of lung cancer cell-induced brain
metastasis
Though one of the lung cancer cell line (HARA-B) induces
bone metastasis [12], it was not known that HARA-B cells
also induce brain metastasis. At 3 weeks after the inocula-
tion of HARA-B cells into cardiac ventricle, metastatic foci
were mainly found in midbrain-lateral cortex (data not
shown). At 4–6 weeks, metastatic foci of various sizes were
found throughout the brain. Bigger metastatic foci attracted
more astrocytes (Fig. 1a), with the correlation factor of
tumor size and GFAP intensity of 0.638 (Fig. 1b). Though
the incidence of brain metastasis was different depending
on each mouse, the highest incidence was generally
observed in cerebral cortex and hippocampus (Fig. 1c). The
correlation factor of tumor size and GFAP intensity was
higher in hippocampus (0.716) than that in cortex (0.4927)
(Fig. 1d). On the other hand, brain’s immune cells,
including microglia and/or invaded macrophages, also
showed accumulation around tumor cells but did not show
stronger correlation between tumor size and immune cell
population (data not shown). These results suggest that
there are correlations between astrocytes and metastatic
tumor cells in the microenvironment of brain metastasis.
Effects of astrocytes on the proliferation of HARA-B
cells in vitro
In order to elucidate the relationship between astrocytes
and HARA-B cells, interaction between 2 cell types was
tested in vitro. Primary cultured mouse astrocytes were
used and co-cultured with HARA-B cells. The proliferation
of HARA-B cells was increased in co-culture with astro-
cytes in comparison to that in the control (in the absence of
astrocytes). In addition, more astrocytes and longer incu-
bation time yielded more proliferation of HARA-B cells
(Fig. 2a). The relative increase of proliferation at a ratio of
HARA-B cells to astrocytes of 1:5 and 1:10 were
285 ± 9.5% (n = 6) and 441 ± 11.2% (n = 6), respec-
tively. Since the proliferation of cells in culture system
depends on the cell number and physical contact, the
effects of conditioned medium on the proliferation of
HARA-B cells were examined. First, to avoid physical
contact, HARA-B cells were cultured in insert-well with
astrocytes in lower-well (ratio of HARA-B to astrocytes
was 1:10). After 48 of insert-culture, the medium was
collected and added to HARA-B cells and incubated for 48
or 72 h, and then the cell number was counted. Since the
Fig. 1 AstrocyteaccumulatesaroundHARA-Bcellsinvivo.aTypical
examples of immunostaining of astrogliosis (GFAP) around invaded
tumor cells (human cytokeratin, CK). Accumulation of GFAP-positive
astrocytes has relation to the size of the tumors. b Correlation between
tumor size and astrogliosis. Accumulation of astrocytes was indicated
as an intensity of GFAP ﬂuorescence. c Typical examples of immuno-
staining indicating more accumulation of astrocytes in hippocampus
than in cerebral cortex. d Correlation curve between tumor size and
GFAPintensityincortex(closedcircle)andhippocampus(opencircle).
In hippocampus, astrogliosis around metastatic tumor foci increased
logarithmically with correlation factor (R
2) of 0.72
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123medium from insert-culture also increased the proliferation
of HARA-B cells, it was suggested that some soluble
factors were induced, presumably in astrocytes, without
physical cell–cell contact between astrocytes and HARA-B
cells (Fig. 2b). Second, it was investigated whether astro-
cyte-induced soluble factors are constitutive or inducible.
Neither astrocyte-conditioned medium (ACM) nor HARA-
B-conditioned medium (HCM) but medium from HCM-
treated astrocytes (H-ACM) signiﬁcantly increased the
proliferation of HARA-B cells after 48 or 72 h of treatment
(Fig. 2c). These results suggest that astrocytes could be
stimulated by some soluble factors released from tumor
cells, and then produce some growth-promoting factors for
tumor cells in turn.
Identiﬁcation of soluble factors produced by astrocytes
To identify growth-promoting soluble factors produced by
astrocytes, mRNA expression of several cytokines and/or
growth factors were examined. Activated astrocytes have
been shown to produce a wide variety of cytokines
including interleukin-1 (IL-1), interleukin-3 (IL-3), inter-
leukin-6 (IL-6), tumor necrosis factor-a (TNF-a), trans-
forming growth factor-b (TGF-b), insulin-like growth
factor-1 (IGF-1) and platelet-derived growth factor (PDGF)
[6–8]. To discriminate astrocytes-derived cytokines
(mouse-origin) from HARA-B-derived cytokines (human-
origin), primers for mouse cytokines which do not cross-
react to human cytokines were used (Table 1). The
ampliﬁcation of mRNA shows that marked increases in the
expression of IL-1b, TNF-a and IL-6 were found in
astrocytes after 72 h in the insert-culture with HARA-B
cells. The relative expression levels of IL-1b, TNF-a and
IL-6 increased to 11.4 ± 2.2, 26.9 ± 1.9 and 15.4 ± 1.1
fold (n = 3 each), respectively. On the other hand,
expressions of EGF, TGF-b, IGF-I and PDGF-B did not
show signiﬁcant change even after 72 h of the insert-cul-
ture with HARA-B cells (Fig. 3a). The RT–PCR for
human-IL-1b, human-TNF-a and human-IL-6 in HARA-B
cells with or without insert-culture with astrocytes was also
performed but the fold increase in mRNA was not signif-
icant for either cytokine (data not shown). These results
suggest that the origin of IL-1b, TNF-a and mouse-IL-6
were astrocytes but not HARA-B cells.
We also measured the protein levels of mouse-IL-1b,
mouse-TNF-a and mouse-IL-6 in the conditioned medium
obtained from single-cultured astrocytes (Astro), insert-
cultured astrocytes (insert-culture), and co-cultured astro-
cytes (co-culture) with HARA-B cells after 72 h incubation.
Signiﬁcant increase in the amounts of IL-1b and TNF-a was
Fig. 2 Astrocyte stimulated the proliferation of tumor cells via
soluble factors. a The normalized number of HARA-B cells increased
according to the ratio of astrocytes to HARA-B cells and incubation
time in co-culture treatment (HARA-B cells : astrocytes = 1:5, A5;
HARA-B cells : astrocytes = 1:10, A10). b Culture medium from
insert-culture of astrocytes with HARA-B cells (HARA-B cells :
astrocytes = 1:10, A10) signiﬁcantly increased the proliferation of
tumor cells compared to the one without insert-culture medium
(control). c H-ACM (HARA-B-stimulated astrocyte-conditioned
medium), but not HCM (HARA-B-conditioned medium) nor ACM
(astrocyte-conditioned medium) signiﬁcantly increased the prolifer-
ation of tumor cells. The incubation time was 48 h (gray bars) and
72 h (black bars). Each value represents the mean ± SEM (n = 6).
** P\0.01
Fig. 3 Expression of mRNA and release of cytokines and growth
factors from activated astrocytes. (a) Quantitative RT–PCR of IL-1b,
IL-6, TNF-a, transforming growth factor-b (TGF-b), insulin-like
growth factor-1 (IGF-1), epidermal growth factor (EGF), and platelet-
derived growth factor-B (PDGF-B) in astrocytes insert-cultured with
HARA-B cells. The expression level of each cytokine or growth
factor mRNA was normalized to the level of each cytokine in
astrocytes cultured alone. The relative values of each cytokine mRNA
in insert-cultured astrocytes for 72 h are shown. Each value represents
the mean ± SEM (n = 3). Release of IL-1b (b), TNF-a (c) and IL-6
(d) into the culture medium of single-culture of astrocytes (Astro),
insert-culture or co-culture of astrocytes and HARA-B cells for 48
and 72 h were detected by ELISA. Each value represents the
mean ± SEM (n = 6). ** P\0.01,
## P\0.01
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123observed after 48 and 72 h of insert-culture and co-culture
(Fig. 3b, c), while the increase in IL-6 release was only
observed after 72 h of insert-culture and co-culture
(Fig. 3d). The amounts of each cytokine after 72 h in
astrocyte-culture, co-culture, and insert-culture were 0 (not
detectable), 8.8 ± 0.7 and 9.4 ± 0.8, pg/ml for IL-1b,
8.3 ± 1.3, 116 ± 5.5 and 121 ± 7.9 pg/ml for TNF-a, and
4.2 ± 1.3, 34.2 ± 1.9 and 40 ± 4.2 pg/ml for IL-6,
respectively (n = 6).
Effects of recombinant IL-1b, TNF-a and IL-6 and their
neutralizing antibodies on the proliferation of HARA-B
cells
To conﬁrm the effects of IL-1b, TNF-a and IL-6, recom-
binant mouse (m) IL-1b, mTNF-a and mIL-6 were applied
to HARA-B cells. The concentrations of IL-1b, TNF-a and
IL-6 used were employed according to the levels of these
cytokines observed in the insert- or co-culture medium
(Fig. 3b, c, d). Mouse-IL-1b in a range of 1-10 pg/ml,
but not high concentration (50 pg/ml), promoted the
proliferation of HARA-B cells (Fig. 4a). Mouse-TNF-a
and mIL-6 (10–500 pg/ml each) showed growth-promoting
effect on HARA-B cells in a dose-dependent manner
(Fig. 4a). These results show that IL-1b, TNF-a and IL-6
released from mouse astrocytes could increase the prolif-
eration of human-origin HARA-B cells.
In reverse, neutralizing antibodies against mIL-1b,
mTNF-a and mIL-6 inhibited the effects of co-culture. The
titrations of each antibody used (mIL-1b and mTNF-a
antibody: 0.2–2.0 lg/ml, mIL-6 antibody: 2.0–20 ng/ml)
were determined according to the maximal neutralizing
concentration (data not shown). The proliferation of
HARA-B cells was promoted to 449 ± 10.2% after
co-culture with astrocytes for 72 h in comparison to that in
the control (single-culture of HARA-B cells). The anti-
bodies against mIL-1b (1 lg/ml), mTNF-a (1 lg/ml), mIL-
6 (10 ng/ml) and all three antibodies were added at 24 h
after the co-culture of HARA-B cells with astrocytes, and
the co-culture were maintained for further 48 h in the
presence of these antibodies. The proliferation of HARA-B
cells was signiﬁcantly attenuated to 149 ± 7.0,
217 ± 10.8, 253 ± 11 and 126 ± 5.9% in the presence of
antibodies against IL-1b, TNF-a, IL-6 and all three anti-
bodies, respectively (n = 5 each) (Fig. 4b).
Identiﬁcation of tumor cell-derived factors which
activate astrocytes
We then identiﬁed HARA-B-derived factors which activate
astrocytes and promote expression of IL-1b, TNF-a, and
IL-6. The factors in HARA-B cells culture medium was
analyzed using the cytokine proteome proﬁler. The
increased expression of cytokines in HARA-B conditioned
medium compared to control (10% FBS DMEM) were
IL-1ra, IL-2, IL-8, MIF, and SERPINE1 (PAI-1) (Fig. 5a).
Among them, IL-8, MIF, and PAI-1 which showed greater
expression were tested whether they really activate mouse
astrocytes and stimulate the production of IL-1b, TNF-a,
and IL-6. The expression of TNF-a mRNAs in astrocytes
were signiﬁcantly increased by recombinant human IL-8
(hIL-8, 10–100 ng/ml) and hMIF (10-100 ng/ml) (n = 3
each) (Fig. 5b). The TNF-a mRNA level was not detected
with the application of hPAI-1 somehow (not shown). The
expression of IL-1b mRNAs in astrocytes were also
signiﬁcantly increased by hIL-8 (100 ng/ml), hMIF
(10–100 ng/ml), and hPAI-1 (100–1000 ng/ml) (n = 3
each)(Fig. 5c).TheexpressionofIL-6mRNAsinastrocytes
were signiﬁcantly increased by hMIF (10–100 ng/ml), and
hPAI-1 (10–100 ng/ml) but not by hIL-8 (n = 3 each)
(Fig. 5d). From these results, tumor-derived MIF would be
the most potential candidate for stimulating astrocyte and
IL-8 and PAI-1 may be less responsible.
Fig. 4 Effects of recombinant cytokines on HARA-B cell prolifer-
ation and inhibitory effects of neutralizing antibodies. a Effects of
recombinant mouse (m) IL-1b (1–50 pg/ml), mTNF-a (10–500 pg/
ml), and mIL-6 (10–500 pg/ml). Data were given as the percentage of
tumor cell proliferation without cytokines (without recombinant
cytokines; 100%). HARA-B cells were cultured for 24 h in DMEM
and then for 48 h in serum free DMEM with each cytokine. Each
value represents the mean ± SEM (n = 6). b Effects of neutralizing
antibodies. Anti-mIL-1b (1 lg/ml), anti-mTNF-a (1 lg/ml), anti-
mIL-6 (10 ng/ml) neutralizing antibodies, all three antibodies (all ab)
and corresponding control IgG were added to co-culture of HARA-B
cells and astrocytes. Antibodies were added after 24 h of co-culture of
HARA-B cells and astrocytes, and then maintained for 48 h with
neutralizing antibodies or control IgG. Data were given as the
percentage of control (single-culture of HARA-B cells; 100%) under
the same condition without adding antibodies. Each value represents
the mean ± SEM (n = 5). ** P\0.01,
# P\0.05
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The expression of receptors for IL-1b, TNF-a and IL-6 on
HARA-B cells were examined by the immunocytochemi-
cal staining. Receptors and receptor subunit for these
cytokines were detected on cytokeratin-positive HARA-B
cells by using antibodies against human-IL-1RtI, human-
TNFRtI, human-IL-6Ra and human-gp130. All of these
receptors were detected in single-cultures of HARA-B cells
(control) (Fig. 6a). To examine the time-dependent change
in the expression level for each cytokine receptor and
receptor subunit on HARA-B cells, the immunostaining
was observed after 24, 48 and 72 h of co-culture with
astrocytes. The semi-quantitative analyses showed that the
expression level for IL-1RtI and TNFRtI decreased with
time after co-culture, while the expression level for IL-6Ra
and gp130 were up-regulated in co-culture with astrocytes
(Fig. 6b). These results suggest that IL-6 receptors on
HARA-B cells may be more functional when HARA-B
cells were co-cultured with astrocytes and IL-6 may be the
most important cytokine in the promotion of HARA-B cell
proliferation in the brain.
Effects of astrocytes on the growth of different lung
tumor cell lines in vitro
To test if the mutual stimulation between astrocytes and
lung cancer cells was general observation and not speciﬁc
to HARA-B cells, three other cell lines derived from
human squamous cell carcinoma (QG56, EBC-1) and non-
small cell lung cancer (PC-9) were examined in vitro.
Primary cultured astrocytes, which were prepared from
C57BL/6 mice brain, were insert-cultured with other lung
tumor cells in the ratio of 1:10 (lung tumor cells : astro-
cytes). The proliferation of each lung tumor cells increased
to 210 ± 27% (QG56, n = 4), 480 ± 43% (EBC-1,
n = 4), and 150 ± 12% (PC9, n = 4) after 72 h of incu-
bation with insert-culture medium (ICM), respectively
(Fig. 7). These results show that astrocytes, activated by
the soluble contact with lung cancer cells, promote not only
the growth of HARA-B cells but also that of other lung
cancer cells, suggesting that mutual activation of astrocytes
and lung tumor cells are common phenomena.
Astrogliosis around human brain metastasis of lung
tumor
Since activated astrocytes gathered around brain metastasis
in model mice, we examined whether the same pathology
was observed in human tissue from brain with lung cancer
metastasis. We observed brain metastasis of lung tumor in
human tissue sections by Hematoxylin-Eosin staining
(Fig. 8a). GFAP-positive astrocytes, which means acti-
vated astrocytes, accumulated around metastatic foci
(Fig. 8b).
Discussion
Certain cancers, i.e. breast cancer and lung cancer, are
liable to metastasize in the brain. The incidence of the
brain metastasis has been increasing in recent years [1]. In
the metastatic process, the microenvironment of the met-
astatic sites plays an important role for tumor cells to
invade and proliferate in the target tissues [2]. Such a
Fig. 5 HARA-B-derived factors which stimulate astrocytes and their
effects on expression of mRNA of inﬂammatory cytokines in
astrocytes. a Cytokine expression in HARA-B cells culture medium
using the proteome proﬁler. The cytokine expression in medium (10%
FBS DMEM) as negative control (upper panel) and in HARA-B
conditioned medium (lower panel), showing the expression of IL-1ra,
IL-2, IL-8, MIF, and SERPINE1 (PAI-1). b–d Expression of mRNA
of inﬂammatory cytokines (TNF-a, IL-1b, IL-6) in astrocytes treated
with each recombinant cytokines (IL-8, MIF, PAI-1). Quantitative
RT–PCR of TNF-a (b), IL-1b (c), and IL-6 (d) in astrocytes treated
with each cytokine released from HARA-B cells IL-8, MIF, and PAI-
1. The expression level of each cytokine was normalized to the level
of each cytokine in non-treated astrocytes. The relative values of each
cytokine mRNA in astrocyte treated with each cytokine for 72 h are
shown. Each value represents the mean ± SEM (n = 3). Data of
PAI-1-treatment was not shown in TNF-a mRNA
Clin Exp Metastasis (2011) 28:13–25 21
123microenvironment contains many resident cell types in
addition to tumor cells as well as migratory hematopoietic
cells.
Though activated astrocytes and soluble factors pro-
duced by glial cells in vivo seem to play an important role
in the development of brain metastases [5], mechanisms of
brain metastases induced by lung cancer cells remained
unclear.
In the present study, histological examination revealed
that activated astrocytes accumulated around the metastatic
foci of human lung cancer-derived cell line, HARA-B
cells, in the brain. Similar accumulation of astrocytes
around brain metastases was also observed in human brain
section from patients with lung cancer metastasis (Fig. 8),
as well as in autopsy cases [14]. In our animal models,
brain metastases were observed not two but three weeks
after intracardiac inoculation of HARA-B cells, mostly in
lateral cortex including hippocampus where more GFAP-
positive astrocytes were observed even in control condition
(data not shown). In later phase of metastases, 4-6 weeks
after inoculation, more metastases were observed in whole
brain, especially in cerebral cortex. These informations
might be useful to understand the process of brain metas-
tasis and its diagnosis.
From our in vitro studies, it was suggested that astro-
cytes, activated by tumor cells even in the absence of
physical contact, promote the proliferation of lung cancer
cells by releasing trophic factors. Using one of the lung
cancer cell lines, HARA-B cells, IL-1b, TNF-a and IL-6
were identiﬁed as astrocyte-oriented factors. It is known
that activated astrocytes produce various inﬂammatory
cytokines. IL-1, one of the inﬂammatory cytokines, has
been shown to stimulate the growth of tumor cells in
hepatic and/or lung metastases of melanoma tumor cells in
vivo [15–17]. Sierra et al. [11] demonstrated that the
growth of the breast cancer cell line, which was derived
from a brain metastasis, was stimulated by the astrocytes
through IL-6, TGF-b and/or IGF-1 in vitro. In brain
metastasis of melanoma cells, it was reported that astro-
cytes produce neurotrophin-regulated heparanase [18, 19].
Recently, it was also reported that epidermal growth factor
receptor (EGFR) and membrane type-1 matrix metallo-
proteinase (MT1-MMP) may be playing an important role
in brain metastasis from lung adenocarcinoma and breast
cancer [20]. All these results suggest that tumor-promoting
Fig. 6 Time-dependent expression of cytokine receptors on HARA-
B cells. a Immunostaining of cytokine receptor and receptor subunit
(IL-6Ra, gp130, TNFRtI and IL-1RtI) on HARA-B cells with or
without co-culture with astrocytes for 24, 48, and 72 h. HARA-B
cells were also immunostained with anti-cytokeratin (CK) antibody.
b Quantiﬁcation of ﬂuorescent intensity for each receptor or receptor
subunit per area of single cell. Data were given as the percentage of
intensity in control HARA-B cells without co-culture (100%). Each
value represents the mean ± SEM (n = 8). ** P\0.01,
## P\0.01
Fig. 7 Increased proliferation of different lung cancer cell lines by
astrocytes in vitro. The proliferation of HARA-B cells (a), QG56 (b),
EBC-1 (c), PC9 (d) were enhanced when they were incubated with
insert-culture medium of astrocytes for 72 h. Each value represents
the mean ± S.E.M (n = 4). *** P\0.005 (signiﬁcance from
control)
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123factors released from astrocytes are different depending on
the type of tumor cells and each type of tumor cells may
play a different role in the microenvironment of metastatic
sites.
So far, a factor produced by HARA-B cells was only a
parathyroid hormone-related protein (PTHrP) [21]. How-
ever, application of PTHrP(1-34) (10
-6 M) alone did not
stimulate the production of IL-6 in astrocytes (supple-
mentary ﬁgure) as was already reported [22]. It was
reported that TNF-a stimulated the production of IL-6 in
astrocytes and PTHrP acted in an additive fashion with
TNF-a to astrocyte-induced expression of IL-6 [22]. In our
case, however, PTHrP rather attenuated the effect of
TNF-a (100 pg/ml) on astrocytic expression IL-6 (supple-
mentary ﬁgure).
In the present study, we found that the production of
IL-8, MIF, and SERPINE1 (PAI-1) were markedly
increased in the medium of HARA-B cell, with less amount
of IL-1ra, IL-2 (Fig. 5a), which increased expression of
TNF-a, IL-1b, and IL-6 in astrocytes (Fig. 5b–d). It was
recently reported that IL-8, as well as IL-6, were induced in
nonsmall-cell lung carcinoma (non-SCLC) cells A549 [23].
In human lung adenocarcinoma cell line CPA-Yang2,
which is highly metastasis cell line, quantitative RT–PCR
showed that ESM1 (Endothelial cell-speciﬁc molecule 1),
VEGF-C (Vascular Endothelial Growth Factor C), IL-6,
IL-8, AR (androgen receptor) genes were overexpressed
[24]. It was also found that IL-8 and matrix metallopro-
teinase-9 (MMP-9) are important cytokines which are
closely related to the growth and metastasis of tumor [25].
Consistently, lung cancer patients had higher levels of
serum and bronchoalveolar lavage ﬂuid IL-6 and serum
IL-8 compared to controls [26].
As for MIF, it is a multifunctional cytokine or an
autocrine- and paracrine-acting cytokine/growth factor,
being overexpressed in lung cancer, and therefore one of
the biomarkers of non-SCLC [27]. The MIF receptor,
CD74, was recently discovered and was found that CD74
and MIF were co-expressed in tumors in close proximity,
and that co-expression of the MIF-CD74 pair was associ-
ated with both higher levels of tumor-associated angio-
genic CXC chemokines and greater vascularity [28].
Importantly, expression level of MIF, together with CD147
proteins, in non-SCLC were related to the metastasis.
Survival rate was markedly lower in patients with high
expression level of MIF or CD147 [29]. It was also shown
that MIF overexpression by adenovirus in human lung
adenocarcinoma cells induces a dramatic enhancement of
cell migration [30].
Urokinase plasminogen activator (uPA) and its inhibitor
PAI-1 stimulate angiogenesis in non-SCLC [31] and a
crucial role of PAI-1 in lung cancer invasiveness and
inﬂuence on prognosis were reported [32–34]. Increased
PAI-1 expression and stabilization of PAI-1 mRNA in
human lung epithelial and carcinoma cells were regulated
by tumor suppressor protein p53 [35]. Taken together,
IL-8, MIF, and PAI-1 in lung cancer cells are important not
only for invasiveness and prognosis but also as stimulants
for astrocytes after brain metastasis.
Stimulated astrocytes by the factors mentioned above
release IL-1b, TNF-a and IL-6. In our present study,
expression of their receptors on HARA-B cells was con-
ﬁrmed immunocytochemically. Interestingly, the time-
dependent change in the expression of receptors for each
cytokine seemed different in vitro. IL-6 receptor and its
subunit, gp130, were up-regulated with time, while
expression of receptors for IL-1b and TNF-a were down-
regulated. It was reported that leukocytes rapidly lose their
surface receptors for TNF and IL-1 upon exposure to
various stimuli in vitro and in fact lipopolisaccharide (LPS)
induced down-regulation of monocyte and granulocyte
receptors for TNF and IL-1 in humans in vivo [36]. In
parallel, the release of IL-6 looked to be delayed compared
to that of IL-1b and TNF-a (Fig. 3b, c, d). Taking account
Fig. 8 Astrocytes accumulate around metastasized lung cancer cells
in human brain. a Hematoxylin and eosin (H & E)-staining of lung
cancer cell metastasis (dark color) in the human brain section.
b Immunostaining of astrocytes and tumor cells from human brain
section. GFAP-positive astrocytes aggregated around cancer cells
(CAM5.2), which looked similar to the brain metastasis of model
mice
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123of these evidences, IL-1b and TNF-a might play an
important role at the beginning, then IL-6 and its receptors
would become more important functionally when brain
metastases take place during long period. This might be the
reason why the effects of neutralizing antibodies against
IL-1b and TNF-a looked apparently robust when they were
added during the ﬁrst 24–72 h of co-culture. Considering
the long-lasting effect of IL-6, blocking IL-6 may be useful
not only for autoimmune and chronic inﬂammatory dis-
eases [37] but also for brain metastasis. In vivo analyses on
the effects of these cytokine blockages are now under
investigation.
The role of activated microglia also needs to be investi-
gated. It was reported that differential reactions of microglia
to brain metastasis of lung cancer [38], showing an obvious
increase in the number of microglia around metastatic lung
cancer mass in the brain. However, only a few microglia
expressedinduciblenitricoxidesynthase(iNOS)andTNF-a
in the region where the tumor mass was situated. In vitro
study,LPS-activatedmicrogliashowedbothapoptoticeffect
and trophic effect, depending on the concentration of
supernatant. Since the mechanism would be different
between LPS- and metastasis-induced microglial activation,
further investigation would be necessary.
In conclusion, the present results showed that the
interaction between metastatic tumor cells and activated
astrocytes are important in creating a favorable microen-
vironment for the tumor cells in the brain. They stimulate
each other; ﬁrst lung tumor cells stimulate astrocytes by
releasing IL-8, MIF, and PAI-1, then activated astrocytes
stimulate the proliferation of tumor cells by releasing
cytokines such as TNF-a, IL-1b, and IL-6. These mutual
relationships may be important to understand how lung
cancer cells metastasize and develop in the brain.
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